C12N 2710/16233
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/16233 (Use of viral protein as therapeutic agent other than vaccine) appears on 4 US grants and 12 published applications in this corpus.
Search patents in C12N- Granted patents
- 4
- Published applications
- 12
- Assignees
- 6
- Inventors
- 10
- Latest grant
- 28 Oct 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2012 | 0 | 1 |
| 2013 | 0 | 1 |
| 2014 | 0 | 2 |
| 2015 | 1 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 4 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 3 |
| 2023 | 0 | 0 |
| 2024 | 1 | 0 |
| 2025 | 2 | 0 |
By publication year.
Recent patents
- Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for treatment of glioblastoma28 Oct 2025US 12,453,762 B2Amal Therapeutics SA
- Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for treatment of colorectal cancer11 Feb 2025US 12,220,450 B2Amal Therapeutics SA
- Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist31 Dec 2024US 12,178,788 B2Amal Therapeutics SA
- Multi-epitopic vaccine17 Nov 2015US 9,187,534 B2Hopitaux Universitaires De Geneve
- Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Glioblastoma9 Jun 2022US 2022/0175933 A1Amal Therapeutics SA
- Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist10 Feb 2022US 2022/0040314 A1Amal Therapeutics SA
- Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Colorectal Cancer3 Feb 2022US 2022/0031850 A1Amal Therapeutics SA
- A Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist17 May 2018US 2018/0133295 A1Amal Therapeutics SA
- Cell Penetrating Peptides and Complexes Comprising the Same17 May 2018US 2018/0133327 A1Amal Therapeutics SA
Most cited
By later US patents